Condition: Prostate Cancer After a Radical Treatment · Biochemical Recurrence of Malignant Neoplasm of Prostate · Biochemical Persistence of Prostate Cancer · Sponsor: Heinrich-Heine University, Duesseldorf
Following numerous retrospective studies and Phase-3-Studies with promising results, \[18F\]PSMA-1007 has been approved by european authorities. Therefore, it is a growing deployment of this diagnostic method anticipated. This study aims to investigate the diagnostic performance and clinical impact in a real-world-evidence in the context of regular clinical care. The evidence generated by this approach is supposed to assist in optimizing the management of prostate cancer patients.
This description comes directly from the study's public registry record.
Emil Novruzov, Medical Doctor · (+49)211 8118540 · Emil.Novruzov@med.uni-duesseldorf.de
Eduards Mamlins, Medical Doctor · (+49)211 8108069 · eduards.mamlins@med.uni-duesseldorf.de
Always discuss trial participation with your own doctor first.
| Department of Nuclear Medicine, Medical Faculty and University Hospital Duesseldorf, Heinrich-Heine-University Duesseldorf | Düsseldorf, North Rhine-Westphalia, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06657131